ReWalk Robotics Ltd. Files Registration Statement for Proposed Initial Public Offering

Yokneam Ilit, Israel / Marlborough, Massachusetts — July 10, 2014 — ReWalk Robotics Ltd. (“ReWalk”) today announced that it has filed a registration statement on Form F-1 with the Securities and Exchange Commission for a proposed initial public offering of shares of its ordinary shares. The number of shares to be offered and the price range for the proposed offering have not yet been determined. ReWalk has applied to list its ordinary shares on the Nasdaq Global Market under the ticker symbol “RWLK.”

Barclays Capital Inc. and Jefferies LLC will act as joint book-running managers for the proposed offering. Canaccord Genuity Inc. will act as co-manager for the proposed offering.

The offering will be made only by means of a prospectus. When available, a copy of the preliminary prospectus relating to the offering may be obtained from either: Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Ave, Edgewood, NY 11717, 888-603-5847, email: Barclaysprospectus@broadridge.com or Jefferies LLC, 520 Madison Ave, 2nd Floor, New York, NY 10022, 877-547-6340, email: Prospectus_Department@Jefferies.com.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold nor may offers to buy these securities be accepted prior to the time the registration statement becomes effective.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About ReWalk Robotics Ltd.

ReWalk Robotics (formerly Argo Medical Technologies) develops, manufactures and markets wearable robotic exoskeletons for people with lower limb disabilities, such as paraplegia. ReWalk’s mission is to fundamentally change the health and life experiences of individuals with spinal cord injury.  ReWalk is proud to offer the only FDA cleared exoskeleton systems in the United States, for rehab and personal use respectively. Founded in 2001, ReWalk Robotics is a global company with headquarters in the US, Germany, and Israel. For more information on ReWalk Robotics and the ReWalk Systems, please visit www.rewalk.com.